Archives

Dose-response relationship seen with risk heightened with longer duration exposure

Larger reductions seen in heart failure-related symptoms and physical limitations for patients with HFpEF, type 2 diabetes

Improvements noted across all outcomes assessed in patients with heart failure with reduced ejection fraction

Accelerated aging associated with increased risk for early-onset tumors, driven by lung, gastrointestinal, uterine cancers

No increase in aspiration or subsequent pneumonia seen among patients undergoing surgical procedures

Vaccination found to be safe and induces polyclonal immune responses against vaccine targets

Small, but significant reduction seen in prostate cancer deaths, but no reduction seen in all-cause mortality

Signature resulting from combining cell-free-miRNAs, exosomal-miRNAs distinguished patients with PDAC from healthy donors

Lower risk for clinically relevant bleeding seen in acute coronary syndrome, with no increase in risk for MACCE

Lower risks for first heart failure hospitalization, total heart failure hospitalization seen with empagliflozin